Greenville, N.C. – Feb. 17, 2014 – A newly FDA approved treatment for advanced prostate cancer is now available in Pitt County. Carolina Radiation Medicine, a division of Radiation Therapy Associates of Western North Carolina, P.A., is the first to offer Xofigo® (Radium-223 dichloride) in the county.
Xofigo® has been shown to increase survival rates and delay complications in patients with advanced stage prostate cancer that has metastasized to bone. Xofigo® received FDA approval last May after extensive research showed patients lived an average of 3.6 months longer with the treatment than without.
According to the National Cancer Institute, an estimated 233,000 men will be diagnosed with prostate cancer and 29,480 will die from the disease in 2014. Treatment options for men whose cancer has metastasized to bone after receiving medical or surgical therapy have been limited.
“We are pleased that Carolina Radiation Medicine is the first in Pitt County to offer this state-of-the-art, life-prolonging cancer therapy to select men with advanced stage prostate cancer,” says Board Certified Radiation Oncologist Ron Allison, M.D. “Xofigo® has the potential to help patients with advanced stage prostate cancer and we are proud to offer this treatment to men in our community.”
Xofigo® is a radiopharmaceutical that is given intravenously once a month for six months. Carolina Radiation Medicine administers the treatment in an outpatient setting, potentially saving patients from incurring out-of-pocket charges commonly found with hospital-based procedures.
Carolina Radiation Medicine is located at 801 W.H. Smith Blvd. Greenville, NC 27834
For more information about our services, visit www.21cOncologyPittCounty.com or call (252) 329-0025.
About 21st Century Oncology:
21st Century Oncology is the largest global, physician led provider of Integrated Cancer Care Services. The Company offers a comprehensive range of cancer treatment services, focused on delivering academic quality, cost-effective patient care in personal and convenient settings. Including the Oncure Transaction, the Company operates 166 treatment centers, including 133 centers located in 16 U.S. states. The Company also operates 33 centers located in six countries in Latin America. The Company holds market leading positions in most of its domestic local markets and abroad.